Severe hepatotoxicity induced by efavirenz in a treatment-naïve, low body mass index HIV-infected, female patient with no hepatitis and other virus co-infections.
Adult
Alkynes
Benzoxazines
/ adverse effects
Body Mass Index
Chemical and Drug Induced Liver Injury
/ etiology
Cyclopropanes
Dideoxynucleosides
/ therapeutic use
Drug Therapy, Combination
Female
HIV Infections
/ drug therapy
Humans
Lamivudine
/ therapeutic use
Reverse Transcriptase Inhibitors
/ adverse effects
Efavirenz
HIV
drug-induced hepatotoxicity
Journal
Ultrastructural pathology
ISSN: 1521-0758
Titre abrégé: Ultrastruct Pathol
Pays: England
ID NLM: 8002867
Informations de publication
Date de publication:
2019
2019
Historique:
pubmed:
4
10
2019
medline:
29
4
2020
entrez:
4
10
2019
Statut:
ppublish
Résumé
Combined antiretroviral therapy (cART) consisting of two nucleoside reverse transcriptase inhibitors (NRTIs) and one non-nucleoside reverse transcriptase inhibitor (NNRTI), such as efavirenz, is still the first-line treatment in resource-limited settings. However, efavirenz has shown strong prominence of disadvantages with variance in plasma concentration and central nervous side effects. Our study presents HIV infected, drug naïve, female patient with relatively low BMI,
Identifiants
pubmed: 31578116
doi: 10.1080/01913123.2019.1673862
doi:
Substances chimiques
Alkynes
0
Benzoxazines
0
Cyclopropanes
0
Dideoxynucleosides
0
Reverse Transcriptase Inhibitors
0
Lamivudine
2T8Q726O95
efavirenz
JE6H2O27P8
abacavir
WR2TIP26VS
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM